Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rockwell Medical, a fully-integrated biopharmaceutical company, has received notice from the Japan Patent Office that it has obtained patent issuance for its GMP formulation of Triferic, the company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
Subscribe to our email newsletter
The patent covers the synthesis and formulation for Rockwell’s pharmaceutical-grade Triferic formula and provides protection through 18 July 2028. Additionally, the patent may be eligible for an extension of up to five years due to time recovered from the regulatory process.
Rockwell Medical founder chairman and CEO Robert L Chioini noted the company is excited to receive this patent protection in Japan, one of the largest dialysis markets in the world and an important target market for Triferic.
"This is another important patent approval for Triferic, and further strengthens our overall IP portfolio for our novel iron-delivery technology," Chioini added.